Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: Association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways

Molecular Cancer Therapeutics

Volumn 1, Issue 9, 2002, Pages 695-706

  Wu, Kongming ^a   Wang, Chenguang ^a   D'Amico, Mark ^a   Lee, Richard J ^a   Albanese, Chris ^a   Pestell, Richard G ^a   Mani, Sridhar ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; CYCLIN D1; ENZYME INHIBITOR; FLAVONOID; FLAVOPIRIDOL; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL DIVISION; CELL SEPARATION; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL SEPARATION; CHROMONES; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; PIPERIDINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; S PHASE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036632965     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K. I., Siegel, P. M., Hung, M. C., Yarden, Y., Horowitz, J. M., Muller, W. J., and Pestell, R. G. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol., 20: 672-683, 2000. (Pubitemid 30023109)
2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987. (Pubitemid 17231334)
3. Kurokawa, H. L. A., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
4. Ciocca, D. R., and Eledge, R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine, 13: 1-10, 2000.
5. Yu, D., Liu, B., Tan, M., Li, J., Wang, S. S., Hung, M. Role of erbB2 in breast cancer chemosensitivity. Bioessays, 22: 673-680, 2000.
6. Yu, D., Liu, B., Tan, M., Li, J., Wang, S. S., and Hung, M. C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via MDR-1-independent mechanisms. Oncogene, 19: 1359-1365, 1996. (Pubitemid 26343590)
7. Baselga, J. Current and planned clinical trials with trastuzumab. Semin. Oncol., 27: 27-32, 2000.
8. Janes, P. W., Daly, R. J., deFazio, A., and Sutherland, R. L. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene, 9: 3601-3608, 1994. (Pubitemid 24359398)
9. Muthuswamy, S. K., Siegel, P. M., Dankort, D. L., Webster, M. A., and Muller, W. J. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell. Biol., 14: 735-743, 1994.
10. Qian, Y-W., Wang, Y-C., Hollingsworth, R. E., Jones, D., Ling, N., and Lee, E. Y. A retinoblastoma-binding protein related to a negative regulator of Ras in yeast. Nature (Lond.), 364: 648-652, 1993. (Pubitemid 23274725)
11. Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., and Arnold, A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev., 20: 501-534, 1999. (Pubitemid 30647078)
12. Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and Pestell, R. G. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem., 270: 23589-23597, 1995.
13. Westwick, J. K., Lambert, Q. T., Clark, G. J., Symons, M., Van Aelst, L., Pestell, R. G., and Der, C. J. Rac regulation of transformation, gene expression and actin organisation by multiple PAK-independent pathways. Mol. Cell. Biol., 17: 1324-1335, 1997. (Pubitemid 27097361)
14. v-src induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways: a role for cAMP response element-binding protein and activating transcription factor-2 in pp60v-src signaling in breast cancer cells. J. Biol. Chem., 274: 7341-7350, 1999.
15. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E. Stat3 as an oncogene. Cell, 98: 295-303, 1999. (Pubitemid 29380565)
16. Matsumura, I., Kitamura, T., Wakao, H., Tanaka, H., Hashimoto, K., Albanese, C., Downward, J., Pestell, R. G., and Kanakura, Y. Transcriptional regulation of cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J., 18: 1367-1377, 1999. (Pubitemid 29110320)
17. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico. M., Pestell, R., and Ben-Ze'ev, A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA, 96: 5522-5527, 1999. (Pubitemid 29234650)
18. D'Amico, M., Hulit, J., Amanatullah, D., Zafonte, B. T., Albanese, C., Maofu Fu, M., Ikui, A., Donehower, L. A., Shtutman, M., Ben-Ze'ev, A., Dedhar, S., Takemaru, K-I., Moon, R. T., and Pestell, R. G. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3β and CREB-dependent pathways. J. Biol. Chem., 275: 32649-32657, 2000.
19. Watanabe, G., Howe, A., Lee, R. J., Albanese, C., Shu, I-W., Karnezis, A. N., Zon, L., Kyriakis, J., Rundell, K., and Pestell, R. G. Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc. Natl. Acad. Sci. USA, 93: 12861-12866, 1996. (Pubitemid 26382734)
20. Diehl, J. A., and Sherr, C. J. A dominant negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation of CDK-activating kinase. Mol. Cell. Biol., 17: 7362-7374, 1997. (Pubitemid 27505965)
21. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.
22. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
23. Yu, Q., Geng, Y., and Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature., 411: 1017-1021, 2001. (Pubitemid 32612319)
24. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. A. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 84: 1736-1740, 1992.
25. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavinoid L86-8275. Biochem. Biophys. Res. Commun., 210: 589-595, 1994.
26. Worland, P. J., Kaur, G., Stetler-Stevenson, M., Sebers, S., Sartor, O., and Sausville, E. A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol., 46: 1831-1840, 1993. (Pubitemid 23349033)
27. 1 arrest with inhibition of cyclin-dependent kinase (cdk) 2 and cdk4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
28. Brusselbach, S., Nettelbeck, D. M., Sedlacek, H. H., and Muller, R. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int. J. Cancer, 77: 146-152, 1998. (Pubitemid 28308564)
29. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996. (Pubitemid 26374418)
30. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998. (Pubitemid 28053367)
31. Patel, V., Senderowicz, A. M., and Decio, P. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig., 102: 1674-1681, 1998. (Pubitemid 28516252)
32. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998. (Pubitemid 28417418)
33. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cell cancer: a University of Chicago Phase II Consortium Study. J. Clin. Oncol., 18: 371-375, 2000. (Pubitemid 30056427)
34. Mani, S., Wang, C., Francis, R., and Pestell, R. G. Cyclin-dependent kinase inhibitors: novel anti-cancer drugs. Exp. Opin. Investig. Drugs, 9: 1849-1870, 2000. (Pubitemid 30639334)
35. Zwijsen, R. M. L., Klompmaker, R., Wientjens, E. B. H. G. M., Kristel, P. M. P., van der Burg, B., and Michalides, R. J. A. M. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol. Cell. Biol., 16: 2554-2560, 1996. (Pubitemid 26161258)
36. Musgrove, E. A., Lee, C. S., Buckley, M. F., and Sutherland, R. L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994. (Pubitemid 24253878)
37. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., and Sausville E. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999. (Pubitemid 29428969)
38. Chou, T-C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
39. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997. (Pubitemid 27355478)
40. Pegram, M., and Lewis, G. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18: 2241-2251, 1999. (Pubitemid 29186925)
41. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem., 270: 27489-27494, 1995.
42. Le, X. F., McWatters, A., Bae, D. S., Mills, G. B., Kumar, R., and Bast, R. C., Jr. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res., 60: 3522-3531, 2000. (Pubitemid 30482172)
43. Wang, C., Fu, M., D'Amico, M., Albanese, C., Brownlee, M., Lisanti, M. P., Chatterjee, K., Lazar, M. A., and Pestell, R. G. Inhibition of cellular proliferation through IκB kinase independent and PPARγ receptor dependent repression of cyclin D1. Mol. Cell. Biol., 219: 3057-3070, 2001. (Pubitemid 32298373)
44. Van den Heuvel, S., and Harlow E. Distinct role for cyclin dependent kinases in cell cycle control. Science (Wash. DC), 262: 2050-2054, 1993. (Pubitemid 24041887)
45. Zafonte, B., Amanatullah, D., Sage, D., and Pestell, R. G. Ras regulation of cyclin dependent immunoprecipitation kinase assays. In: W. E. Balch, C. J. Der, and A. Hall (eds.), Methods in enzymol regulators and effectors of small GTPases, Vol. 322, pp. 116-124. San Diego: Academic Press, 2001.
46. Lybarger, L., Dempsey, D., Franek, K. J., and Chervenak, R. Rapid generation and flow cytometric analysis of stable GFP-expressing cells. Cytometry, 25: 211-220, 1996. (Pubitemid 26386318)
47. Choi, M. Mechanism of transforming growth factor-β1 signaling: role of the mitogen-activated protein kinase. Kidney Int., 58: 53-58, 2000.
48. Douziech, N., Calvo, E., Laine, J., and Morisset, J. Activation of MAP kinases in growth responsive pancreatic cancer cells. Cell Signalling, 11: 591-602, 1999. (Pubitemid 29255891)
49. Bouzahzah, B., Fu, M., Iaavarone, A., Factor, V. M., Thorgeirsson, S. S., and Pestell, R. G. Transforming growth factor β1 recruits histone deacetylase 1 to a p130 repressor complex in transgenic mice in vivo. Cancer Res., 60: 4531-4537, 2000. (Pubitemid 32103636)
50. Amundadottir, L. T., and Leder, P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene, 16: 737-746, 1998. (Pubitemid 28076084)
51. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., and Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15: 2452-2467, 1996. (Pubitemid 26151185)
52. Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., and Ullrich, A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J., 14: 4267-4275, 1995.
53. Galaktionov K., and Beach, D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell, 67: 1181-1194, 1991. (Pubitemid 121001530)
54. Hoffman, I., Dreatta, G., and Karsenti, E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J., 13: 4302-4310, 1994. (Pubitemid 24295202)
55. Blomberg, I., and Hoffman., I. Ectopic expression of cdc25A accelerates the G1/S transition and leads to premature activation of cyclin E-and cyclin A-dependent kinases. Mol. Cell. Biol., 19: 6183-6194, 1999.
56. Slikowski, M. X., Lewis, G. D, Hotaling, T. E., Fendly, B. M., and Fox, J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol., 26 (Suppl. 12): 60-70, 1999. (Pubitemid 29411434)
57. Nelson, J. M., and Fry, D. W. Akt, MAPK (Erk 1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem., 276: 14842-14847, 2001.
58. 1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J. Biol. Chem., 275: 6987-6995, 2000.
59. Nakamura, N., Vazquez, F., Vazquez, F., Signoretti, S., Loda, M., and Sellers, W. R. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol., 20: 8969-8982, 2000. (Pubitemid 32245927)
60. Graff, J. R., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., Vessella, R. L., and Neubauer, B. L. Increased Akt activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem., 11: 24500-24505, 2000. (Pubitemid 30626543)
61. Gingras, A. C., Kennedy, S. G., O'Leary. M. A., Sonenberg, N., and Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev., 15: 502-513, 1998. (Pubitemid 28101013)
62. Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., and Rosen, N. J. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 6: 29864-29872, 1998. (Pubitemid 28510001)
63. Kaiser, A., Nishi, K., Gorin, F. A., Walsh, D. A., Bradbury, E. M., and Schnier, J. B. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys., 386: 179-187, 2001. (Pubitemid 32989307)
64. Boerner, S. A., Tourne, M. E., Kaufmann, S. H., and Bible, K. C. Effect of P-glycoprotein on flavopiridol sensitivity. Br. J. Cancer, 84: 1391-1396, 2001. (Pubitemid 32522110)
65. Bible, K. C., Bible, R. H., Kottke. T. J., Svingen, P. A., Xu, K., Pang, Y. P., Hajdu, E., and Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 60: 2419-2428, 2000.
66. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31799, 2001.
67. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., and Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., 275: 28345-28348, 2000.